Immunotherapy is one of the newest treatments in the fight against cancer. Bispecific antibody immunotherapy adds a new dimension that may bring even more hope to cancer patients. Join the Cancer Support Community’s Senior Director of Education, Rachel Saks, MSS, LSW, OSW-C, for a talk with Ian Flinn, MD and learn about this innovative new cancer treatment. Dr. Flinn is the Director of Lymphoma Research at the Sarah Cannon Research Institute. Dr. Flinn also serves as the director for the Sarah Cannon Center for Blood Cancer at Tennessee Oncology and TriStar Centennial Medical Center.
They will discuss what bispecific antibody immunotherapy drugs are and how these therapies work. They will also talk about which drugs the U.S. Food and Drug Administration has approved, common side effects, and what patients should think about when considering these
drugs.
This program was made possible with generous support by Amgen.